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ABSTRACT
Objective: To identify genetic risk factors associated with susceptibility to age-related cognitive
decline in African Americans (AAs).
Methods: We performed a genome-wide association study (GWAS) and an admixture-mapping
scan in 3,964 older AAs from 5 longitudinal cohorts; for each participant, we calculated a slope
of an individual’s global cognitive change from neuropsychological evaluations. We also per-
formed a pathway-based analysis of the age-related cognitive decline GWAS.
Results: We found no evidence to support the existence of a genomic region which has a strongly
different contribution to age-related cognitive decline in African and European genomes. Known
Alzheimer disease (AD) susceptibility variants in the ABCA7 andMS4A loci do influence this trait
in AAs. Of interest, our pathway-based analyses returned statistically significant results high-
lighting a shared risk from lipid/metabolism and protein tyrosine signaling pathways between
cognitive decline and AD, but the role of inflammatory pathways is polarized, being limited to
AD susceptibility.
Conclusions: The genetic architecture of aging-related cognitive in AA individuals is largely similar
to that of individuals of European descent. In both populations, we note a surprising lack of enrich-
ment for immune pathways in the genetic risk for cognitive decline, despite strong enrichment of
these pathways among genetic risk factors for AD. Neurol Genet 2017;3:e125; doi: 10.1212/
NXG.0000000000000125
GLOSSARY
AA 5 African American; AD 5 Alzheimer disease; CHAP 5 Chicago Health and Aging Project; EA 5 European ancestry;
GWAS 5 genome-wide association study; IIDP 5 Indianapolis-Ibadan Dementia Project; MAP 5 Rush Memory and Aging
Project; MARS 5 Minority Aging Research Study; ROS 5 Religious Orders Study; SNP 5 single nucleotide polymorphism.
Aging-related cognitive decline is a multifactorial process and is likely to be promoted by accu-
mulated brain injury due to chronic conditions of aging, including Alzheimer disease (AD),1
cardiovascular risk factors,2 type II diabetes mellitus,3,4 cerebrovascular diseases,2 and inflam-
matory diseases.5
When trajectories of cognitive decline are compared between individuals of African American
(AA) ancestry and individuals of non-Hispanic European ancestry (EA), there is no appreciable
difference at the average rate of decline in these 2 populations.6 However, differences in the
prevalence and effect size of different risk factors for cognitive decline—such as AD, small and
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large vessel neurovascular disease, and lipid
profiles—have been noted previously.7,8 These
differences suggest that it is important to
explore the role of such risk factors in distinct
human populations so that interventions to
mitigate cognitive decline can be more effec-
tively targeted.
To identify genetic loci influencing age-
related cognitive decline in AAs, we first used
admixture mapping, an approach that scans
the genome for disease-related genetic variants
that differ in frequency across populations.9 In
addition, we performed a genome-wide associ-
ation study (GWAS) using the same 3,964 AA
participants and outcome measure to identify
genetic variants that are associated with the
individual’s trajectory of cognitive decline.
We evaluated the mechanism of the association
by examining pathologic phenotypes, gene
expression, and biological pathway data.
Together, these analyses shed light on the role
of genetic ancestry and on genes and pathways
that contribute to the pathogenesis of age-
related cognitive decline in AAs.
METHODS Additional information is included in the e-Methods
at Neurology.org/ng.
Study participants and cohorts. Samples are from partici-
pants in 5 longitudinal studies of cognition, the Religious Orders
Study (ROS), the Rush Memory and Aging Project (MAP), the
Chicago Health and Aging Project (CHAP), the Minority Aging
Research Study (MARS), and the Indianapolis-Ibadan Dementia
Project (IIDP). A description of the original cohorts contributing
samples is provided in the e-Methods.
Clinical and cognitive evaluation. Table e-1 summarizes the
specific longitudinal cognitive measures that are collected in each
cohort. A detailed description of the clinical and cognitive evalu-
ation and statistical modeling is provided in the e-Methods.
Genotyping, quality control, and genotype imputation.
DNA from participants was extracted from whole blood, lym-
phocytes, or frozen postmortem brain tissue. The CHAP and
IIDP participants were genotyped on the Illumina Human
Omni1Quad. The ROS, MAP, and MARS participants were
genotyped on the Illumina Omni Express. We used BEAGLE
software to impute the ungenotyped markers using reference
haplotype panels from the 1000 Genomes Project (Phase I
Version 3).10 EIGENSTRAT software11 was used to calculate
eigenvectors that explained genetic differences in ancestry
among participants in the study (figure e-1). A description
of the genotype imputation and quality control is provided
in the e-Methods.
Genome-wide association studies. We tested the association
of each imputed single nucleotide polymorphism (SNP) (allelic
dosages) and residual cognitive decline slope extracted from the
mixed-effects models. The association analysis was performed
using linear regression (with the first 2 ancestry principal
components as a covariate) using the PLINK toolkit.12 The
meta-analysis was performed using METAL software.13
Admixture analysis. To detect chromosomal segments of dis-
tinct ancestry in AAs, we used the HAPMIX algorithm.9 The
quantitative and case-control admixture scan was performed
using MIXSCORE (version 1.3) software.14 A description of
the admixture analysis is provided in the e-Methods.
Pathway and protein-protein interaction analysis. We per-
formed a pathway enrichment analysis using MAGENTA soft-
ware15 and adopting Ingenuity and BIOCARTA databases as
pathway information resources.
A protein-protein interaction network was reconstructed with
the online tool DAPPLE16 with 1,000 permutations and 2 inter-
acting binding degrees as a cutoff.
Gene expression quantitative trait locus analysis. The gene
expression data from primary CD141CD162 monocytes and
CD41 T cells from 461 healthy humans are part of the Immu-
nological Variation Project.17 A description of the expression
analysis is provided in the e-Methods.
Standard protocol approvals, registrations, and patient
consents. All blood draws and data analyses were performed in
compliance with protocols approved by the institutional review
boards of each institution. Written informed consent was ob-
tained from all participants.
RESULTS Demographic and phenotypic characteristics
of participants. After stringent data quality control,
3,964 AA individuals from 5 study cohorts (CHAP,
IIDP, ROS, MAP, and MARS) were available for
our analysis (table e-2). All of these cohorts recruit
participants who are older than 65 years and do not
have dementia at the time of enrollment. The partic-
ipants are then followed longitudinally using a battery
of cognitive tests. A subject’s performance on each
test was standardized, and an average aggregate mea-
sure of global cognitive performance was computed
for each evaluation.18 Each individual had 2 or more
neuropsychological evaluations, and a linear mixed-
effects model was used to calculate a residual that
captures the slope of an individual’s global cognitive
change (figure e-2; e-Methods). This residual was
then used as a quantitative trait in our analyses, as
we have done in a prior GWAS.19
Genome-wide admixture scan for age-related cognitive
decline. To examine whether genetic ancestry influen-
ces age-related cognitive decline in AA participants, we
conducted a genome-wide admixture study. This
technique estimates the proportion of African or EA
that is present at every point in the genome of each
individual. The estimated average percentage of EA
in the AA participants used in this analysis was
21.2 6 12.3%, consistent with other studies of AA
participants9,20 (figure e-3).
In our primary analysis, we performed a quantita-
tive admixture evaluation,14 which associates local
ancestry to the continuous phenotype—in this case,
the slope of cognitive decline. The quantitative
2 Neurology: Genetics
admixture scan did not identify any single region of
the genome that meets the stringent threshold of
genome-wide significance (p , 1 3 1025) (figure
1A). We also conducted a different admixture scan
using an “extreme of outcome” strategy. Specifically,
we defined the top 20% of individuals (n 5 792) in
the distribution of cognitive decline trajectories as
“cases” and the 20% with lowest cognitive decline
trajectories as “controls.” In this analysis, we observed
no admixture peak of excess European or African
ancestry in the cases relative to the control partici-
pants, consistent with the results of the quantitative
admixture scan (figure 1B). However, while no single
chromosomal region shows a statistically significant
difference in ancestry, we find that cases have a higher
proportion of African ancestry across their genome
compared to controls (80.0% 6 11.4% African
ancestry in cases and 78.4% 6 13.3% in controls; t
test p , 0.0001). This result suggests that there may
be several different regions of the genome that con-
tain risk alleles that are more frequent in AA popula-
tions but that each of them may have only a modest
influence on the risk of cognitive decline.
GWAS for age-related cognitive decline. While genetic
ancestry at any single locus does not appear to have
a strong role in age-related cognitive decline, genetic
variants do influence this trait.19,21–24 We therefore
proceeded with a GWAS meta-analysis across the 5
AA cohorts (n 5 3,964 participants) to identify
common genetic variants that contribute to age-
related cognitive decline. Quantile-quantile plots of
the distribution of test statistics showed little
deviation from the expected null distribution over
most of the genome (figure 2A), and the genomic
inflation factor (lGC) was 0.997, indicating no
substantial population stratification in the study.
The top results of the GWAS are listed in table
1. As expected, common variants such as rs429358
that partially reflect the effect of the APOE locus7,25
showed association at a genome-wide level of sig-
nificance, consistent with the previously reported
role of the APOE e4 haplotype in cognitive
decline.19 In addition to APOE, we discovered 20
loci with suggestive (p , 1026) and 4 loci (nearest
genes are TRPS1, TEK, GABRA4, and ZNF737)
with highly suggestive (p , 1027) levels of associ-
ation to the rate of cognitive decline in our study
(table 1; figure 2B).
The highly suggestive variant rs16885997 is
located 911 kb from TRPS1, a gene encoding a zinc
finger transcription factor that represses GATA-
regulated genes and binds to a dynein light chain
protein. Of interest, the TRPS1 haplotype associated
Figure 1 Genome-wide quantitative admixture scans in 3,964 African Americans
(A) Locus-specific quantitative admixture association scan. The plot shows2log10-transformed p values for all genotyped single nucleotide polymorphisms. The
dotted gray line indicates genome-wide significant threshold for admixture association. (B) Case-control admixture analysis using an extreme of outcome strategy.
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with a higher rate of cognitive decline has previ-
ously been associated with greater total (p 5 2 3
1028) and high-density lipoprotein (p5 63 10211)
cholesterol levels,26 suggesting a possible link with
neurovascular disease.
A complementary strategy to evaluate the role of
the 4 highly suggested loci involves their evaluation
in network analyses: specifically, we assessed
whether the genes found within these 4 loci con-
nect to an existing AD susceptibility network. Of
interest, in a protein-protein interaction analysis
using DAPPLE, the TEK gene on chr 9p21 (table
1) interacts with validated AD susceptibility genes
identified in a recent GWAS25 including CD2AP,
PTK2B, BIN1, and INPP5D (figure e-4). This net-
work analysis is significant (permuted p 5 0.021),
suggesting that the TEK locus may have a role in
cognitive decline through an effect on known AD
susceptibility networks.
Since AD susceptibility alleles have been reported
to influence the trajectory of cognitive decline,19,21 we
also evaluated the role of the known AD risk alleles
discovered in EA participants in our AA results. As
outlined in table e-3, we find evidence that the index
SNPs in the ABCA7 and MS4A loci are associated
with age-related cognitive decline in AAs using
a gene-based multiple hypothesis correction.27
Immune system–mediated pathways are enriched in the
AD GWAS but not in cognitive decline. To systemati-
cally identify biological connections between putative
susceptibility loci in our analysis, we conducted
a pathway enrichment analysis using MAGENTA
software15 and highly curated databases as pathway
information resources. We found evidence of enrich-
ment of associations involved in lipid/cholesterol
metabolism and protein tyrosine kinase signaling
pathways in relation to cognitive decline in AA par-
ticipants (figure 3). We replicated the role of these 2
pathways in an analysis of the same trait in the par-
ticipants of EA from the ROS and MAP cohorts
(table e-4).
Figure 2 Genome-wide association study meta-analysis of 3,964 African Americans
(A) Quantile-quantile (QQ) plot of the genome-wide association study (GWAS) meta-analysis. Expected 2log10 p values are
those expected under the null hypothesis. Observed are the GWAS association results derived by linear regression of all
imputed and genotyped single nucleotide polymorphisms (SNPs). (B) Manhattan plot of the cognitive decline GWAS meta-
analysis. The plot shows 2log10-transformed p values for all 13.9M SNPs tested. AA 5 African American.
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We then compared our pathway enrichment re-
sults for cognitive decline with results for AD suscep-
tibility using data from a recent large AD GWAS.25
In the AD GWAS pathway analysis, we found that
cholesterol/lipid metabolism and immune processes
were enriched (p , 1023; false discovery rate 0.1).
When comparing our AA cognitive decline results
with the results of a similar analysis in relation to AD
in AA participants using a recently published study,7
we find that “lipid/cholesterol metabolism” and
“protein kinase signaling processes” are enriched in
both analyses, but we observed striking polarization of
immunity-related pathways in the AD GWAS (figure
3; table e-3). The pathways including “complement
activation,” “interferon-mediated immunity,” and
“NF-kappaB cascade” are enriched for AD GWAS
results but not for loci associated with cognitive
decline (figure 3). These results suggest that, propor-
tionally, the involvement of innate immunity may be
much more important in AD than that in aging-
related cognitive decline.
DISCUSSION Our large study represents an impor-
tant step forward in understanding the role of genetic
risk factors in aging-related cognitive decline in the
AA population. We were well powered to find
susceptibility loci of an even modest effect in our
Table 1 Top results of genome-wide scan for the rate of age-related cognitive decline in African Americans
Single nucleotide polymorphism Allele
Minor allele
frequency b p Value (meta-analysis) Nearest gene(s)
rs429358 C/T 0.198 20.01 1.92E-14 TOMM40, APOE
rs16885997 T/G 0.077 20.009 2.52E-07 TRPS1, CSMD3
rs73643144 C/T 0.103 20.007 4.10E-07 TEK, ncRNA32
rs17641411 T/C 0.013 20.026 5.05E-07 COX7B2, GABRA4
chr19:20843676 G/A 0.022 20.037 7.43E-07 ZNF737, ZNF626
chr10:114847180 T/A 0.016 20.029 1.22E-06 VTI1A, TCF7L2
chr1:3293503 G/T 0.011 20.048 1.31E-06 ACTRT2, PRDM16
chr5:76620888 C/T 0.017 20.012 1.35E-06 C16orf13, UBE2CBP
chr3:29995897 G/A 0.034 20.016 1.47E-06 AZI2, ZCWPW2
chr15:82531032 T/C 0.035 20.019 2.04E-06 EFTUD1, FAM154B
chr16:6473466 T/G 0.017 20.018 2.28E-06 TMEM114, C16orf68
rs10865419 C/A 0.152 20.007 2.54E-06 C2orf3, LRRTM4
rs4719128 T/C 0.302 20.004 2.70E-06 AUTS2, WBSCR17
chr20:54981371 C/T 0.025 20.032 3.03E-06 CSTF1, CASS4
rs12654437 G/T 0.363 0.004 4.43E-06 GRAMD1A, TTLL2
rs2717504 G/C 0.205 0.005 4.78E-06 VIT, STRN
rs6939297 A/G 0.066 20.009 4.97E-06 SCAND3, RPSAP2
chr14:30517407 A/G 0.011 20.02 5.42E-06 G2E3, SCFD1
chr2:235031272 A/G 0.016 20.031 6.33E-06 SPP2, ARL4C
rs2343732 C/T 0.113 20.007 6.42E-06 PDGFC, GLRB
Figure 3 Pathway enrichment analysis of African American age-related
cognitive decline and Alzheimer disease genome-wide association
studies
The figure plots the 2log10 (false discovery rate [FDR] q value) derived using MAGENTA
for pathways enriched in association for Alzheimer disease susceptibility on the y axis,
and the results of the same analysis for the genetic architecture of aging-related cogni-
tive decline that we define in our participants on the x axis. The dotted lines denote the
threshold of significance (FDR , 0.05) in each analysis. Each point represents one path-
way; enriched pathways are color coded with the color key included at the top right
aspect of the figure. Selected pathways are annotated to illustrate the types of path-
ways that we find to be enriched.
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admixture analysis, but we failed to find any single
locus with a significant association in this analysis
that relies on differences in the genetic risk between
the AA and EA populations. Thus, we have not
found evidence to support the existence of genetic
risk factors that are unique to AA individuals and
have a strong effect on aging-related cognitive
decline at the population level.
Nonetheless, the greater average proportion of
African ancestry in AA individuals with more rapid
cognitive decline suggests that there are likely to
be a number of genetic risk factors that, while shared
between African and European populations, may
have a more detrimental role in AA participants.
Such a variant may have a more detrimental role
for the AA population because of an increase in fre-
quency, a larger effect size, or an interaction with an
environmental variable that is enriched in AA
individuals.
Our study holds many other intriguing results that
warrant further investigation such as the low fre-
quency variants that are strongly associated with cog-
nitive decline in AA individuals and are not found in
EA individuals. This prevents us from evaluating
these variants in existing data from EA participants,
and thus, replication in large cohorts of AA partici-
pants will be necessary to validate these observations.
Similarly, the other suggestive association of the TEK
locus, which connects to a pathway of validated AD
susceptibility genes, will require further investigation
in AA participants given the very low frequency of the
risk allele in EA populations. Finally, we also exam-
ined the role of the most suggestively associated var-
iants in the published results of the AD GWAS in AA
participants, and we saw no association with this dif-
ferent trait, although this study is not powered to rule
out a modest effect in AD for the variants that we
report in this study.
Leveraging several large recent studies of AD and
cognitive decline in AA and EA participants in
addition to our new AA study, we report an intrigu-
ing perspective on broader patterns in the genetic
architecture of AD and cognitive decline. The fact
that certain pathways are significantly enriched for
associations with both traits is not surprising since
AD is an important driver of cognitive decline in
older age. However, the degree of polarization in
the enrichment of immune pathways is striking
and was unexpected. While there are certainly some
susceptibility variants for cognitive decline with
presumed effects on immune function (such as
MS4A genes and perhaps TRPS1), the relative role
of immune pathways is clearly different in terms of
susceptibility to these 2 conditions. This is impor-
tant in prioritizing target validation and drug dis-
covery efforts in shared pathways as well as framing
the deployment of compounds that may be discov-
ered in the future: patient stratification may be
required to develop an optimal therapy for an indi-
vidual, based on the relative role of different path-
ophysiologic processes that contribute to that
individual’s cognitive decline.
Overall, this study illustrates the successful appli-
cation of a study design that does not target cognitive
performance in older age—which is an amalgam of
the effects of developmental factors, life experience,
and degenerative processes—but rather targets cogni-
tive decline. This trait allows us to specifically inter-
rogate the genetic architecture of factors that
contribute to cognitive loss with age, which occurs
in all participants, regardless of their maximal cogni-
tive attainment. Our focus on cohorts that represent
samples of the older population makes our results
relevant to the experience of our aging population,
particularly the AA population. Our pathway analyses
are consistent with the narrative that neurovascular
risk factors, as well as AD risk factors, are important
for cognitive well-being in older age in AA individuals
and individuals of other ancestries. The admixture
analyses highlight the fact that there are probably
no genetic risk factors for cognitive decline that are
common and unique to populations with African
ancestry: such genetic risk factors appear to be present
in both the European and African component of an
AA individual’s genome, but the allele frequency and
effect size of a susceptibility variant can vary between
populations, making an allele easier to discover in one
or another population.
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